《Table 2Treatment outcomes (n=44) .》
本系列图表出处文件名:随高清版一同展现
《"KML001, an arsenic compound, as salvage chemotherapy in refractory biliary tract cancers: A prospective study"》
*ECOG PS and morphine need variances were evaluated in 42 patients,excluding two patients lost to follow-up.AEs:adverse events;CR:complete response;PR:partial response;SD:stable disease;PD:progressing disease;IQR:interquartile range;ECOG PS:Eastern Cooper
Forty-four patients(21 women,23 men)were enrolled between November 2011 and October 2014.Characteristics of these patients are summarized in Table 1.The mean age was 61.5±8.9 years.There were 17 patients(38.6%)with intrahepatic cholangiocarcinoma,nine patients(20.5%)with perihilar cholangiocarcinoma,seven patients(15.9%)with extrahepatic cholangiocarcinoma,and11 patients(25.0%)with gallbladder cancer.There were three patients(6.8%)with locally advanced disease and 41 patients(93.2%)with metastatic disease.Baseline ECOG PS scores were 0 in six patients(13.6%),1 in 24 patients(54.5%),and 2 in 14 patients(31.8%).The median ECOG PS score was 1(IQR,1–2)in the entire cohort.
图表编号 | XD0031707100 严禁用于非法目的 |
---|---|
绘制时间 | 2019.02.15 |
作者 | Jung Hyun Jo、Huapyong Kang、Hee Seung Lee、Moon Jae Chung、Jeong Youp Park、Seungmin Bang、Seung Woo Park、Si Young Song |
绘制单位 | Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine、Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine、Division of G |
更多格式 | 高清、无水印(增值服务) |